GESOM: G-POEM for Refractory Gastroparesis After Esophagectomy With Gastric Pull-through

Sponsor
Institute for Clinical and Experimental Medicine (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06068127
Collaborator
Jackson Memorial Hospital and the Lennar Foundation Medical Center (Other), Universitäres Speiseröhrezentrum Hamburg (Other), University Hospital, Martin (Other), The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology (Other), Regional Institute of Gastroenterology, Cluj-Napoca (Other), Universitätsklinikum Augsburg (Other), Universitätsspital Zürich (Other), Universitaire Ziekenhuizen KU Leuven (Other), King Edward VII's Hospital/King's College Hospital (Other), John Hopkins Hospital (Other), Columbia University Irving Medical Centre (Other), A. Gemelli IRCCS Polyclinic Foundation (Other), Humanitas Research Hospital Milan (Other), University Hospital of Marseille (Other), Sana-Klinikum Lichtenberg (Other)
30
5

Study Details

Study Description

Brief Summary

This is a retrospective study assessing the effectiveness of endoscopic pyloromyotomy in patients suffering from gastroparesis and/or symptoms of delayed gastric emptying after esophagectomy with gastric pull-through. Several, mainly European, centres which perform G-POEM on a routine basis will be asked to participate. The main reason to assess the effectiveness of G-POEM in this specific subgroup of patients is the fact this specific subgroup of patients is often being excluded from trials assessing efficacy and safety of G-POEM.

The participating centres will be asked to report appropriate patients among those who have undergone G-POEM since 2015 till December 2023. Patients fulfilling inclusion and not having exclusion criteria will be included into the analysis; the minimum follow-up is set to 6 months after G-POEM. The main outcome is the symptomatic response at 6, 12 and 24 months (measured by GCSI score). Other endpoints will be change in other symptoms not covered by GCSI, change in gastric emptying rate and safety of the procedure.

For each enrolled patient a case report form (CRF) will be filled in and delivered to the leading centre via an online database or in other forms if preferred by the respective centres. The leading centre will be responsible for data collection and analysis.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    30 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Retrospective
    Official Title:
    Retrospective Study of Per-oral Endoscopic Pyloromyotomy (G-POEM) in Patients With Refractory Gastroparesis After Esophagectomy With Gastric Pull-through
    Anticipated Study Start Date :
    Jan 1, 2024
    Anticipated Primary Completion Date :
    May 31, 2024
    Anticipated Study Completion Date :
    May 31, 2024

    Outcome Measures

    Primary Outcome Measures

    1. GCSI score [At baseline and 3, 6, 12, 24, 36 months after G-POEM]

      Gastroparesis Cardinal Symptom Index questionnaire: The score ranges from 0 to 5 for each symptom (9 questions) and these are averaged into subscores and into a total score (also ranging from 0 to 5). Higher scores indicate more severe symptoms.

    Secondary Outcome Measures

    1. Gastric emptying by scintigraphy [At baseline and 3, 6, 12, 24, 36 months after G-POEM]

      Gastric scintigraphy protocol endorsed by both American Neurogastroenterology and Motility Society and American Nuclear Medicine Society will be used to assess gastric emptying with a standard 200 kcal, 2% fat egg-substitute test meal. Gamma camera images will be obtained immediately after meal ingestion and then at 1, 2, 3 and 4 hours. Diagnostic criterion for delayed gastric emptying is defined as the percentage of gastric retention >60% at 2 h or ≥ 10% at 4 h or both. Half-time (T1/2) emptying time will also be calculated. At least 72 hours before gastric emptying test, narcotics and other medications that can interfere with gastric emptying will be discontinued.

    2. Gastric emptying by breath test [At baseline and 3, 6, 12, 24, 36 months after G-POEM]

      Gastric emptying assessed using 13C breath test with octanoic acid. This measurement is an alternative to the measurement of gastric emptying by scintigraphy. The choice depends on the practice in a particular center.

    3. Pyloric distensibility [At baseline and 3, 6, 12, 24, 36 months after G-POEM]

      Pyloric distensibility measured by impedance planimetry (EndoFLIP device)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients who underwent G-POEM after esophagectomy with a gastric pull-through for confirmed (scintigraphy or breath test) or presumed gastroparesis. (Some centres perform G-POEM in patients whose gastroparesis was not confirmed by a scintigraphy or a breath test, therefore it is only presumed. This particular subset of patients will be analysed separately.)

    • Total GCSI score before G-POEM at least 1.0.

    • At least 6 months follow-up after G-POEM.

    Exclusion Criteria:
    • Organic pyloric obstruction

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Institute for Clinical and Experimental Medicine
    • Jackson Memorial Hospital and the Lennar Foundation Medical Center
    • Universitäres Speiseröhrezentrum Hamburg
    • University Hospital, Martin
    • The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology
    • Regional Institute of Gastroenterology, Cluj-Napoca
    • Universitätsklinikum Augsburg
    • Universitätsspital Zürich
    • Universitaire Ziekenhuizen KU Leuven
    • King Edward VII's Hospital/King's College Hospital
    • John Hopkins Hospital
    • Columbia University Irving Medical Centre
    • A. Gemelli IRCCS Polyclinic Foundation
    • Humanitas Research Hospital Milan
    • University Hospital of Marseille
    • Sana-Klinikum Lichtenberg

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Doc. (Ass. prof.) Jan Martinek, MD, PhD, AGAF, Prof. Jan Martínek, MD, PhD, AGAF, Institute for Clinical and Experimental Medicine
    ClinicalTrials.gov Identifier:
    NCT06068127
    Other Study ID Numbers:
    • GESOM
    First Posted:
    Oct 5, 2023
    Last Update Posted:
    Oct 5, 2023
    Last Verified:
    Oct 1, 2023
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 5, 2023